56 Results for "

H2AX

" in MedChemExpress (MCE) Product Catalog:
Products (56)

56 Results for "H2AX" in MCE Product Catalog:

37
37 Publications Verification
Cat. No.: HY-18174
CAS No.: 1234015-52-1
Synonyms: LY2606368
Research Areas:  

Cancer

Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity [2].
loading...
    loading...
37
37 Publications Verification
Cat. No.: HY-18174A
CAS No.: 1234015-54-3
Synonyms: LY2606368 dihydrochloride
Research Areas:  

Cancer

Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dihydrochloride inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity [2].
loading...
    loading...
37
37 Publications Verification
Cat. No.: HY-18174E
CAS No.: 1234015-58-7
Synonyms: LY2606368 dimesylate
Research Areas:  

Cancer

Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity [2].
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-117693
CAS No.: 299953-00-7
Purity:  98.62%
Target:  

ATM/ATR

Research Areas:  

Cancer

(E/Z)-Mirin is a mixture of (E)-Mirin and Mirin ((Z)-Mirin) (HY-19959) configurations. Among them, Mirin is an inhibitor of MRN (Mre11-Rad50-Nbs1). Mirin prevents MRN-dependent ATM activation without affecting ATM protein kinase activity [2].
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-123834
CAS No.: 824983-91-7
Purity:  99.85%
Target:  

FLAP ATM/ATR

Research Areas:  

Cancer

FEN1-IN-1 (compound 1) is a small molecule flap endonuclease 1 (FEN1) inhibitor with antitumor activity. FEN1-IN-1 binds to the active site of FEN1 and partly achieves inhibition by the co-ordination of Mg 2+ ions. FEN1-IN-1 initiaties a DNA damage response and activates the ATM checkpoint signalling pathway, the phosphorylation of histone H2AX and the ubiquitination of FANCD2 in mammalian cells. FEN1-IN-1 is promising for research of cancers .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-12037A
CAS No.: 592542-59-1
Purity:  99.01%
Synonyms: ON-01910
Research Areas:  

Cancer

Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle [2]. Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-12037
CAS No.: 592542-60-4
Purity:  99.57%
Synonyms: ON-01910 sodium
Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle [2]. Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-101089
CAS No.: 390362-78-4
Purity:  99.88%
Target:  

Telomerase Apoptosis

Research Areas:  

Cancer

RHPS4 is a potent telomerase inhibitor (IC50 = 0.33 μM). RHPS4 is a DNA damage inducer [2].
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-122181
CAS No.: 2093400-18-9
Purity:  98.55%
Research Areas:  

Cancer

OTS186935 is a potent protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 regulates the production of γ-H2AX in cancer cells .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2445
CAS No.: 37308-75-1
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer [2] .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-122181B
Purity:  99.58%
Research Areas:  

Cancer

OTS186935 hydrochloride is a potent protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 hydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 hydrochloride regulates the production of γ-H2AX in cancer cells .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N0316
CAS No.: 55481-88-4
Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway [2] .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-103241
CAS No.: 293762-45-5
Purity:  99.10%
Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces 42-induced cytotoxicity (EC50 of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response [2]. Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P80161

Host:  

Rabbit

Application:  

WB, ICC/IF, IHC-P, IP

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P80821
Synonyms: H2A.X; H2AFX; H2a/x; HIST5-2AX; Histone H2A.X; gamma H2A.X

Host:  

Rabbit

Application:  

WB, IHC-P, ICC/IF, IP

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80941
Synonyms: H2A.X; H2AFX; H2a/x; HIST5-2AX; Histone H2A.X; gamma H2A.X

Host:  

Mouse

Application:  

WB, ICC/IF

Reactivity:  

Human, Mouse

loading...
    loading...
Cat. No.: HY-W1126504
CAS No.: 3066864-32-9
Synonyms: MC339
Target:  

Notch

Research Areas:  

Cancer

ETN029 (MC339) is a selective DLL3 ligand. ETN029 labeled with 225Ac has dose-dependent cytotoxicity in SCLC, NEPC and metastatic melanoma cells and increases the phosphorylation of H2AX expression. ETN029 labeled with 177Lu shows rapid uptake persistent tumor retention and favorable tumor-to-kidney ratio. ETN029 can be used for cancers like SCLC and NEPC imaging and research [2].
loading...
    loading...
Cat. No.: HY-163944
CAS No.: 3081311-94-3
LL-K12-18 is a CDK12 kinase inhibitor and a dual-site molecular glue. LL-K12-18 inhibits human CDK12 with an IC50 value of 283.9 nM, and selectively degrades cyclin K via the ubiquitin-proteasome system by stabilizing the CDK12-DDB1 complex. LL-K12-18 downregulates DNA damage response genes, reduces the phosphorylation level of CTD Ser2 in RNA polymerase II, and modulates biomarkers such as ATM, RAD51, γ-H2AX and cleaved PARP, thereby effectively inducing apoptosis and inhibiting proliferation of breast cancer cells. LL-K12-18 exhibits high target selectivity and serves as a research tool for studies on triple-negative breast cancer [2].
loading...
    loading...
Cat. No.: HY-122182
CAS No.: 2093401-33-1
Purity:  98.64%
Research Areas:  

Cancer

OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .
loading...
    loading...
Cat. No.: HY-158975
CAS No.: 3050772-20-5
Purity:  98.69%
Target:  

Casein Kinase VRK

Research Areas:  

Cancer

VRK1/CK1-IN-1 (compound 36) is a dual VRK1 and CK1 family inhibitor, with a Ki of 37.9 nM against human VRK1, 8.3 nM against human CK1δ, and 7.8 nM against human CK1ε. VRK1/CK1-IN-1 exhibits extremely low activity against VRK2. VRK1/CK1-IN-1 can be used in studies related to p53-deficient tumors .
loading...
    loading...